EVElena Valassi

Elena Valassi

*This is an algorithmically generated author record based on publicly available information.

Elena Valassi has a total of 428 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pituitary adenomas in older patients: approaches, challenges, and future directions

    by Sandrine A Urwyler, Daniela Esposito, Athanasios Fountas, Georgia Ntali, Elena Valassi, Niki Karavitaki

    Several pituitary adenomas are diagnosed at an old age. Over the decades, the increase in life expectancy has led to fundamental changes in the age structure of the society. As a result of this, the number of elderly patients newly diagnosed or living with a pituitary adenoma is increasing. Clinical phenotypes in this group often differ from that encountered in younger patients, and ageing can have a negative impact on pituitary adenoma-related comorbidities. Timely diagnosis may be influenced by factors including confusion with physical changes occurring during normal ageing, presence of visual abnormalities mimicking those caused by pituitary adenomas, and age-related alterations in pituitary function. In this review, we present data on various types of pituitary adenomas diagnosed in the elderly from the published literature of the last 20 years, discuss differences with younger patients, and highlight diagnostic and therapeutic challenges in this field. Overall, essential priority is to offer a patient-tailored management strategy, which will be effective, safe, pragmatic, enhancing optimal age-adjusted quality of life and considering patient wishes and frailty. Directing the management to centres of excellence with proven and established surgical/endocrine expertise combined with wider multi-disciplinary input will serve this priority.

  • Open Access

    MRI-based radiomics prediction of somatostatin receptor ligand response in acromegaly: an automated pipeline study

    by Sabina Ruiz, Roger Mateu-Estivill, Ariadna Izquierdo-Gómez, Miriam López-Máñez, Jesús A Alzate, Gemma Monté-Rubio, Maria de la Iglesia-Vayá, Marta Araujo-Castro, Betina Biagetti, Silvana Sarria-Estrada, et al.

    Context: Radiomics may capture tumor characteristics predicting therapeutic response. Objective: To develop an MRI-based radiomics pipeline for predicting response to SRLs in acromegaly. Methods: MRI data from 267 subjects across 3 datasets were used to develop an automated tumor detection and segmentation pipeline (Spanish multicenter acromegaly IGTP cohort, n = 81; 2 public datasets, n = 186). The 3-stage pipeline comprised: (1) automated tumor detection (YOLOv8), (2) 3D segmentation (SegResNet), and (3) radiomic feature extraction (PyRadiomics) with supervised classification. Treatment-response radiomics included contrast-enhanced T1-weighted (Ce-T1W1) MRI from 49 patients treated with SRL. SRL response was defined as ≥50% IGF-1 reduction or normalization. Eleven machine-learning classifiers were evaluated using stratified repeated k-fold cross-validation. Results: Automated segmentation achieved a Dice coefficient of 0.795 using combined Ce-T1WI and T2-weighted images (T2WI), decreasing to 0.765 in the acromegaly-specific cohort. The best-performing model was a 3-feature logistic regression classifier, with an out-of-fold AUC of 0.798 (95% CI: 0.671-0.918), balanced accuracy of 0.793, F1-score of 0.815, and correct classification of 39/49 patients (79.6%). Performance improved as the radiomic feature set was reduced from 5 to 2. The most consistent feature was log-sigma-3-0-mm-3D_glcm_ClusterShade, which appeared in 98% of cross-validation folds and contributed most to the model-derived discriminative signal. Conclusion: In this multicenter radiomics study of SRL response prediction in acromegaly, an automated pipeline achieved good discriminative performance (AUC = 0.798). These findings highlight both the promise and the current challenges of radiomics-based treatment prediction.

  • Open Access

    Approach to the patient: Precision Medicine–Guided Evaluation and Treatment of Acromegaly

    by Manel Puig-Domingo, Montserrat Marques-Pamies, Miguel Sampedro, Joan Gil, Marta Araujo-Castro, Rebeca Martínez-Hernández, Betina Biagetti, Mireia Jordà, Elena Valassi, Mónica Marazuela

    Acromegaly is a heterogeneous disease in which delayed biochemical control remains common despite the availability of multiple therapeutic options. Traditional stepwise medical treatment algorithms often rely on the use of first-generation somatostatin ligands (fgSRLs) as the first line drugs with the empirical escalation and trial-and-error approaches, prolonging patients’ exposure hormonal excess. Cluster analyses indicate that overall, three main classes of patients with acromegaly representing distinct biological phenotypes can be recognized: (1) young patients with invasive macroadenomas and frequent resistance fgSRLs; (2) older patients with noninvasive tumors and SRL responsiveness in the majority of them; and (3) patients with intermediate features often requiring combination medical therapy in whom prediction of response is more challenging. From a practical perspective, biomarker-guided treatment selection based on T2-weighted MRI signal intensity, the short acute octreotide test, and tumor immunohistochemistry, following the strategy validated in the ACROFAST study, is applicable in clinical practice. It allows a prompt biochemical control and tumor volume reduction, a rationale leading to superior effectiveness performance than the classic sequencing therapy involving the universal utilization of fgSRLs as first option. In the era of integrative and participative medicine, such a protocol enables the early identification of most patients unlikely to respond to fgSRLs, thus supporting timely initiation of pegvisomant, pasireotide or combination therapy, and to achieve hormonal control in nearly 80% of patients. Conclusions: Precision medicine has become a practical reality in acromegaly. A biomarker-guided strategy improves therapeutic efficiency and should be incorporated into contemporary clinical practice.


  • Top Cited Papers
    Open Access

    Consensus on acromegaly complications: an update

    by Andrea Giustina, Luigi di Filippo, Maria Fleseriu, Rosario Pivonello, Stephan Petersenn, John Wass, Susan L. Samson, Alberto M. Pereira, Raúl M. Luque, Betina Biagetti, et al.

    The 16th Acromegaly Consensus Conference in September 2024 updated recommendations on diagnosis and treatment of acromegaly comorbidities. Since the 2020 acromegaly comorbidity management guideline was published, new evidence has emerged on novel and known comorbidities and new treatment approaches. Forty-three experts in the management of acromegaly reviewed the current literature and assessed changes in clinical practice standards and management. Current outcome goals were considered and updated, with a focus on the impact of current and emerging treatments of these comorbidities. Participants assessed factors that determine pharmacological choices, as well as use of specific agents in the management of the most relevant acromegaly comorbidities. We present consensus recommendations highlighting optimization of evidence-based acromegaly comorbidities management.


  • Open Access

    Cost-effectiveness of personalized medical treatment in acromegaly: a post hoc analysis of the ACROFAST study

    by Montserrat Marques-Pamies, Laura Ricou, Joan Gil, Miguel Sampedro-Núñez, Betina Biagetti, Olga Giménez-Palop, Marta Hernández, Silvia Martínez, Cristina Carrato, Rocío Villar-Taibo, et al.

    Context Medical treatment of acromegaly is currently performed through a trial-and-error approach using first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs, with an efficacy of 50%. Some biomarkers can predict patient response, potentially benefiting nonresponders by using personalized treatment approaches. The ACROFAST study revealed that the probability of disease control was 2.53 times higher (CI 1.30-4.80) with personalized treatment, and insulin-like growth factor 1 (IGF1) normalization occurred in 78% vs 53% of patients, compared with standard treatment (P < .05). Objective To evaluate the cost-effectiveness of personalized medicine based on predictive biomarkers, from the results of the ACROFAST study. Methods Post hoc analysis from the ACROFAST study comparing cost-effectiveness of a protocol of medical treatment based on predictive biomarkers to fgSRLs (n = 32) vs standard treatment (n = 36) for 12 months. Costs analyzed were visits, examinations, study of biomarkers (121€/patient), and pharmacological treatment according to the prices established by the Spanish National Health Care System. Medium-term costs were evaluated, considering a projection of up to 2 years in uncontrolled cases, assuming positive and negative scenarios with additional monitoring costs and a 25% likelihood of disease progression per follow-up visit. Results The personalized protocol reduced the average cost per patient required to achieve disease control by 22% (15 127€ vs 19 420€). These results represent an annual saving of 15 263€ per patient achieving hormonal control compared to the standard treatment. Conclusion Personalized medicine, using a relatively straightforward biomarker-based protocol, enables a greater proportion of patients to attain hormonal control and proves to be a cost-effective strategy for managing acromegaly.


  • Open Access

    European Society for Paediatric Endocrinology (ESPE) and European Society of Endocrinology (ESE) joint clinical practice guidance for healthcare transition from paediatric to adult endocrine care

    by Enora Le Roux, Kirstine Stochholm, Martin Fassnacht, Imelda Coyne, Philippe Touraine, Krystallenia I Alexandraki, Malgorzata Wasniewska, Judith P van Eck, Victoria Di Guisto, Amanda Helm, et al.

    Background: The transition from paediatric to adult healthcare is a critical period for young individuals with endocrine conditions. Despite numerous published recommendations, Europe still lacks recent, comprehensive, evidence-based, and practically applicable guidelines for endocrine healthcare transition. Objective: To develop European consensus guidance for transition from paediatric to adult care in endocrine conditions through a structured, evidence-based approach. Methods: A systematic literature review identified 351 recommendations from 55 articles (2011-2023). Articles were included if they provided recommendations on transition from paediatric to adult care for patients with endocrine diseases or general (non-disease-specific) transition guidance. The guidance was developed by a core multidisciplinary group (n = 7) and refined through focus groups with 18 experts from 10 European countries, representing both paediatric and adult care settings. Patient representatives have reviewed and approved it. Results: The guidance includes recommendations across 11 domains: structure of transition service, patient empowerment, patient–professional relationship, multidisciplinary team organization, healthcare provider education, timing and planning, care coordination, management of non-attendance, psychological support, parents/caregivers role, and readiness tools. Each recommendation was rated as either “recommend” (strong) or “suggest” (conditional) based on expert consensus and available evidence. Conclusion: This ESE-ESPE guidance provides a comprehensive, practical framework for endocrine healthcare transition, applicable across different European healthcare settings. The recommendations emphasise structured programs, care coordination, and patient-centred approaches to optimize transition outcomes.


  • Open Access

    Prevalence, risk factors and management of bone complications in Cushing's syndrome across Europe. Data from the European Registry on Cushing's syndrome (ERCUSYN)

    by Aleksandra Zdrojowy-Wełna, Claudia Amaral, Marta Araujo-Castro, Nienke Biermasz, Marek Bolanowski, Jens Bollerslev, Thierry Brue, Davide Carvalho, Frederic Castinetti, Filippo Ceccato, et al.


  • Open Access

    Assessing the Value of Data-Driven Frameworks for Personalized Medicine in Pituitary Tumours: A Critical Overview

    by Joan Gil, Paula de Pedro-Campos, Cristina Carrato, Pol Jardí-Yanes, Montserrat Marques-Pamies, Helena Rodríguez-Lloveras, Anna Rueda-Pujol, Jennifer Marcos-Ruiz, Elena Martinez-Saez, Clara V. Alvarez, et al.

    Background: Pituitary neuroendocrine tumours (PitNETs) are clinically and biologically heterogeneous neoplasms that remain challenging to diagnose, prognosticate, and treat. Although recent WHO classifications using transcription-factor-based markers have refined pathological categorisation, histopathology alone still fails to predict tumour behaviour or support individualised therapy. Objective: This systematic review aimed to evaluate how machine learning (ML) and knowledge extraction approaches can complement pathology by integrating multi-dimensional omics datasets to generate predictive and clinically meaningful insights in PitNETs. Methods: The review followed the PRISMA 2020 statement for systematic reviews. Searches were conducted in PubMed, Google Scholar, arXiv, and SciSpace up to June 2025 to identify omics studies applying ML or computational data integration in PitNETs. Eligible studies included original research using genomic, transcriptomic, epigenomic, proteomic, or liquid biopsy data. Data extraction covered study design, ML methodology, data accessibility, and clinical annotation. Study quality and validation strategies were also assessed. Results: A total of 726 records were identified. After the reviewing process, 98 studies met inclusion criteria. PitNET research employed unsupervised clustering or regularised regression methods reflecting their suitability for high-dimensional omics datasets and the limited sample sizes. In contrast, deep learning approaches were rarely implemented, primarily due to the scarcity of large, clinically annotated cohorts required to train such models effectively. To support future research and model development, we compiled a comprehensive catalogue of all publicly available PitNET omics resources, facilitating reuse, methodological benchmarking, and integrative analyses. Conclusions: Although omics research in PitNETs is increasing, the lack of standardised, clinically annotated datasets remains a major obstacle to the development and deployment of robust predictive models. Coordinated efforts in data sharing and clinical harmonisation are required to unlock its full potential.

  • Benefits of a 12 weeks-individually tailored physical activity program in patients with Cushing’s disease in remission and controlled acromegaly

    by Luciana Martel-Duguech, Helena Bascuñana, Víctor Priego Corredor, Oriol González-Viñuela, Judith Vinyals Ribé, Toni Caparrós Pons, Susan M. Webb, Elena Valassi

    Background Patients with controlled Cushing’s disease (CD) and acromegaly (ACRO) often experience persistent musculoskeletal dysfunction and impaired quality of life (QoL) despite biochemical normalization. Although undergoing supervised physical activity is a clear unmet need of pituitary patients, evidence on the effectiveness of individually tailored exercise programs in these populations is scanty. Objective The aim of this pilot study was to evaluate the effectiveness of a 12-week individually tailored and supervised exercise program on muscle function and patient-reported outcomes (PROMs) in patients with biochemically controlled CD and ACRO. Methods Twenty patients (10 women with CD in remission, 10 men with controlled ACRO) participated in a structured program combining aerobic and resistance exercises, supervised by professional trainers, three times a week over 12 weeks. Outcomes assessed at baseline and post-intervention included, grip strength and physical performance on gait speed, timed up-and-go, chair stand test, muscle structure and quality on ultrasound examination and QoL, as evaluated using disease-specific (CushingQoL, AcroQoL) and generic (SF-12, PANAS, PHQ-9, and GAD-7) questionnaires. Results After the 12-week intervention, significant improvements were observed in physical performance tests (p < 0.05 for all parameters vs. baseline) in both CD and ACRO patients. Ultrasound-measured muscle thickness increased CD patients after completion of the program (p < 0.05), while a decreased echogenicity was found in ACRO patients (p < 0.05) CD patients demonstrated significant improvements in waist circumference, diastolic blood pressure (p < 0.05). No significant changes were observed in PROMs in either group after the intervention. Conclusion An individually tailored, supervised, 12-week exercise intervention significantly enhanced muscle structure and physical performance in patients with controlled CD and ACRO. Further randomized controlled studies are required to confirm the clinical effectiveness of incorporating supervised exercise programs into multidisciplinary management for pituitary disease patients.


  • Open Access

    Corrigendum: Circulating miR-28-5p is overexpressed in patients with sarcopenia despite long-term remission of Cushing’s syndrome: a pilot study

    by Marta Seco-Cervera, José Santiago Ibáñez-Cabellos, Federico V. Pallardo, José-Luis García-Giménez, Anna Aulinas, Luciana Martel-Duguech, Susan M. Webb, Elena Valassi, Jos

    Incorrect Funding In the published article, there was an error in the Funding statement. [The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article ]. The correct Funding statement appears below.FUNDING"This work was supported by a grant from the Instituto de Salud Carlos III (FIS PI21/01223), European Regional Development Fund (FEDER) funds". The authors apologize for this error and state that this does not change